Related Experiment Videos

beta Cell autoimmunity in a child with M.O.D.Y. (Maturity Onset Diabetes in the Young)

E Ortega-Rodriguez1, C Levy-Marchal, S Guillermine

  • 1Pediatric Endocrine and Diabetes Unit, INSERM U457, Robert Debré Hospital, Paris, France. eduardoortega@mixmail.com

Diabetes & Metabolism
|March 10, 2001
PubMed

Insights

We identified a family with MODY type 2 diabetes where a child also had beta cell autoimmunity and HLA DQB1 risk factors for type 1 diabetes. Autoantibody screening is recommended for genetically defined diabetes to rule out concurrent type 1 diabetes risk.

Area of Science:

  • Endocrinology
  • Genetics
  • Immunology

Background:

  • Monogenic forms of diabetes, such as Maturity-Onset Diabetes of the Young (MODY), are genetically distinct from type 1 diabetes mellitus (T1DM).
  • Distinguishing between monogenic diabetes and autoimmune diabetes is crucial for appropriate management and prognosis.

Observation:

  • A family with a confirmed MODY type 2 (HNF1A-MODY) diagnosis was studied.
  • One child in the family presented with beta cell autoimmunity and carried specific HLA DQB1 alleles, indicating a genetic predisposition to T1DM.

Findings:

  • The co-occurrence of MODY type 2 and markers for T1DM autoimmunity highlights potential overlaps in genetic susceptibility.
  • The presence of beta cell autoantibodies and specific HLA types in a genetically defined MODY patient suggests a risk for developing T1DM.

Implications:

  • Genetic screening for diabetes should consider the possibility of concurrent autoimmune processes.
  • Testing for beta cell autoantibodies is recommended in MODY patients, especially those with genetic risk factors for T1DM.
  • This case underscores the importance of comprehensive diagnostic evaluation in diabetes mellitus to ensure accurate classification and prevent misdiagnosis.

Related Concept Videos